Previous Close | 7.63 |
Open | 7.35 |
Bid | 7.05 x 0 |
Ask | 7.12 x 0 |
Day's Range | 7.35 - 7.35 |
52 Week Range | 4.58 - 11.50 |
Volume | |
Avg. Volume | 0 |
Market Cap | 380.365M |
Beta (5Y Monthly) | 1.45 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
BRISBANE, Calif., April 19, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 15, 2024, CareDx granted an option to purchase 700,706 shares of CareDx’s common stock (the "Inducement Option") and 487,804 restricted stock units (the "Inducement RSUs" ) to Jo
BRISBANE, Calif., April 16, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company’s Board of Directors, effective April 15, 2024.
BRISBANE, Calif., April 09, 2024--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx and study collaborators will be presenting the latest data featuring CareDx’s cardiothoracic portfolio at the International Society for Heart and Lung Transplantation (ISHLT) 44th An